Targeting MSR1+ tumor-associated macrophages enhances the therapeutic efficacy of anti-PD-L1 in Hepatocellular carcinoma by suppressing NF-κB pathway activation - PubMed
4 hours ago
- #Tumor-associated macrophages
- #Immunotherapy
- #Hepatocellular carcinoma
- MSR1+ tumor-associated macrophages (TAMs) play a significant role in Hepatocellular carcinoma (HCC) by promoting an immunosuppressive tumor microenvironment.
- High levels of MSR1+ TAMs are associated with poor prognosis in HCC patients.
- MSR1 enhances IL-6 secretion via NF-κB pathway activation, leading to myeloid-derived suppressor cells (MDSCs) recruitment and reduced CD8+ T cell function.
- Combined inhibition of MSR1 and PD-L1 in preclinical models significantly reduces tumor growth more effectively than single treatments.
- Targeting MSR1+ TAMs can overcome resistance to anti-PD-L1 therapy, offering a new immunotherapeutic strategy for HCC.